CY1114977T1 - Στοματικες μορφες δοσολογιας της βενδαμουστινης - Google Patents
Στοματικες μορφες δοσολογιας της βενδαμουστινηςInfo
- Publication number
- CY1114977T1 CY1114977T1 CY20141100174T CY141100174T CY1114977T1 CY 1114977 T1 CY1114977 T1 CY 1114977T1 CY 20141100174 T CY20141100174 T CY 20141100174T CY 141100174 T CY141100174 T CY 141100174T CY 1114977 T1 CY1114977 T1 CY 1114977T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutically acceptable
- vendamostein
- dosage
- oral forms
- bentamustine
- Prior art date
Links
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229920001400 block copolymer Polymers 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000008389 polyethoxylated castor oil Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08075915 | 2008-12-03 | ||
| EP09796303.7A EP2367542B1 (en) | 2008-12-03 | 2009-12-03 | Oral dosage forms of bendamustine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114977T1 true CY1114977T1 (el) | 2016-12-14 |
Family
ID=40588059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100174T CY1114977T1 (el) | 2008-12-03 | 2014-03-05 | Στοματικες μορφες δοσολογιας της βενδαμουστινης |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20120003305A1 (enExample) |
| EP (1) | EP2367542B1 (enExample) |
| JP (1) | JP5778037B2 (enExample) |
| KR (1) | KR101688038B1 (enExample) |
| CN (2) | CN105363037B (enExample) |
| AU (1) | AU2009321745B2 (enExample) |
| BR (1) | BRPI0922806B8 (enExample) |
| CA (1) | CA2745525A1 (enExample) |
| CO (1) | CO6400183A2 (enExample) |
| CY (1) | CY1114977T1 (enExample) |
| DK (1) | DK2367542T3 (enExample) |
| EA (1) | EA020354B1 (enExample) |
| ES (1) | ES2451540T3 (enExample) |
| HR (1) | HRP20140204T1 (enExample) |
| IL (1) | IL213270A (enExample) |
| MX (1) | MX2011005643A (enExample) |
| NZ (1) | NZ592970A (enExample) |
| PL (1) | PL2367542T3 (enExample) |
| PT (1) | PT2367542E (enExample) |
| RS (1) | RS53201B (enExample) |
| SI (1) | SI2367542T1 (enExample) |
| SM (1) | SMT201400053B (enExample) |
| UA (1) | UA102120C2 (enExample) |
| WO (1) | WO2010063493A1 (enExample) |
| ZA (1) | ZA201103791B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011260615B2 (en) * | 2010-06-02 | 2016-11-17 | Pharma& Schweiz Gmbh | Oral dosage forms of bendamustine |
| JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| CN102375044B (zh) * | 2010-08-18 | 2015-04-08 | 重庆华邦胜凯制药有限公司 | 一种盐酸苯达莫司汀中间体z6有关物质的分析方法 |
| ES2613838T3 (es) * | 2011-09-26 | 2017-05-26 | Fresenius Kabi Oncology Ltd | Un procedimiento mejorado para la preparación de hidrocloruro de bendamustina |
| AU2012332767C1 (en) * | 2011-10-31 | 2017-02-02 | Genentech, Inc. | Antibody formulations |
| EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
| PT2656843E (pt) | 2012-04-26 | 2015-04-14 | Helmut Schickaneder | Ésteres de bendamustina e compostos relacionados e a sua utilização médica |
| EP2917183A1 (en) * | 2012-11-12 | 2015-09-16 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
| CA2904143A1 (en) | 2013-03-12 | 2014-10-09 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
| JP2016153374A (ja) * | 2013-06-25 | 2016-08-25 | シンバイオ製薬株式会社 | 炎症性疾患を治療又は予防するための医薬組成物 |
| CN109953954A (zh) | 2013-08-27 | 2019-07-02 | V·沃道里斯 | 苯达莫司汀医药组合物 |
| AU2018346395A1 (en) | 2017-10-05 | 2020-04-30 | Mecox Curemed Co., Ltd. | Oral bendamustine formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US132502A (en) * | 1872-10-22 | Improvement in machines for removing snow from railroads | ||
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| CN101052396A (zh) * | 2004-11-05 | 2007-10-10 | 赛福伦公司 | 癌症治疗 |
| EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CN101119708B (zh) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀冻干药物组合物 |
| CN101028249A (zh) * | 2007-04-12 | 2007-09-05 | 济南康泉医药科技有限公司 | 一种含新生血管抑制剂及烷化剂的抗癌组合物 |
| CN101045058A (zh) * | 2007-04-28 | 2007-10-03 | 济南帅华医药科技有限公司 | 一种含烷化剂及激素类药物的抗癌组合物 |
| CN101084876A (zh) * | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
| US20090130198A1 (en) * | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
| US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
-
2009
- 2009-12-03 NZ NZ592970A patent/NZ592970A/xx unknown
- 2009-12-03 CA CA2745525A patent/CA2745525A1/en not_active Abandoned
- 2009-12-03 MX MX2011005643A patent/MX2011005643A/es active IP Right Grant
- 2009-12-03 PL PL09796303T patent/PL2367542T3/pl unknown
- 2009-12-03 UA UAA201106235A patent/UA102120C2/ru unknown
- 2009-12-03 US US13/132,263 patent/US20120003305A1/en not_active Abandoned
- 2009-12-03 CN CN201510849775.0A patent/CN105363037B/zh not_active Expired - Fee Related
- 2009-12-03 ES ES09796303.7T patent/ES2451540T3/es active Active
- 2009-12-03 AU AU2009321745A patent/AU2009321745B2/en not_active Ceased
- 2009-12-03 PT PT97963037T patent/PT2367542E/pt unknown
- 2009-12-03 HR HRP20140204AT patent/HRP20140204T1/hr unknown
- 2009-12-03 EP EP09796303.7A patent/EP2367542B1/en active Active
- 2009-12-03 JP JP2011538906A patent/JP5778037B2/ja not_active Expired - Fee Related
- 2009-12-03 KR KR1020117015292A patent/KR101688038B1/ko not_active Expired - Fee Related
- 2009-12-03 EA EA201190011A patent/EA020354B1/ru unknown
- 2009-12-03 BR BRPI0922806A patent/BRPI0922806B8/pt not_active IP Right Cessation
- 2009-12-03 WO PCT/EP2009/008857 patent/WO2010063493A1/en not_active Ceased
- 2009-12-03 CN CN2009801547145A patent/CN102281871A/zh active Pending
- 2009-12-03 DK DK09796303.7T patent/DK2367542T3/da active
- 2009-12-03 RS RS20140111A patent/RS53201B/sr unknown
- 2009-12-03 SI SI200930877T patent/SI2367542T1/sl unknown
-
2011
- 2011-05-24 ZA ZA2011/03791A patent/ZA201103791B/en unknown
- 2011-05-31 IL IL213270A patent/IL213270A/en active IP Right Grant
- 2011-06-28 CO CO11080792A patent/CO6400183A2/es not_active Application Discontinuation
-
2013
- 2013-07-01 US US13/932,785 patent/US20140018334A1/en not_active Abandoned
-
2014
- 2014-03-05 CY CY20141100174T patent/CY1114977T1/el unknown
- 2014-04-22 SM SM201400053T patent/SMT201400053B/xx unknown
-
2015
- 2015-04-24 US US14/695,527 patent/US20150335588A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/174,467 patent/US10543196B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201190011A1 (ru) | Пероральные лекарственные формы бендамустина | |
| CY1119177T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| CY1119248T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CY1120796T1 (el) | Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων | |
| CY1117237T1 (el) | Συνθεσεις σταθερων τιακουμυκινων | |
| CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
| CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
| BR112012024796A2 (pt) | inibidores de integrase macrocíclicos | |
| ATE536172T1 (de) | Ezetimibzusammensetzungen | |
| MX390625B (es) | Inhibidores selectivos de jak1. | |
| TW200745078A (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
| CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| MD20160012A2 (ro) | Formulare de inhibitori SYK | |
| EA201070483A1 (ru) | Новые офтальмологические композиции | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| EA201390662A1 (ru) | Фармацевтическая композиция, содержащая дутастерид | |
| EA201300617A1 (ru) | β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ | |
| MX2013007892A (es) | Derivados de fenetilsulfona isoindolina y su uso. | |
| EA201291104A1 (ru) | Пероральные лекарственные формы бендамустина | |
| AR064152A1 (es) | Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion. | |
| WO2008004100A3 (en) | Therapeutic compounds | |
| WO2008039894A3 (en) | Atorvastatin pharmaceutical compositions | |
| CY1114306T1 (el) | Νεα συνθεση για τη θεραπευτικη αντιμετωπιση της ιδιοπαθους θρομβοκυτταραιμιας |